公开(公告)号：US10913738B2

公开(公告)日：2021-02-09

申请号：US16484604

申请日：2018-02-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04 ,  A61P29/00 ,  A61P19/02 ,  A61P17/06 ,  A61P1/00

Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

公开(公告)号：US11767322B2

公开(公告)日：2023-09-26

申请号：US17503516

申请日：2021-10-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael C. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20220388987A1

公开(公告)日：2022-12-08

申请号：US17743615

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20220315580A1

公开(公告)日：2022-10-06

申请号：US17116016

申请日：2020-12-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20170022192A1

公开(公告)日：2017-01-26

申请号：US15289437

申请日：2016-10-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Zhang ,  Qingjie Liu

IPC: C07D417/14 ,  C07B59/00 ,  C07D403/12 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14 ,  C07D417/12 ,  C07D413/12 ,  C07D401/12 ,  C07D237/24

CPC classification number: C07D417/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D237/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract translation: 或其立体异构体或药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如本文所定义，可用于调节IL-12，IL-23和/或IFNα，通过作用于Tyk-2 引起信号转导抑制。

公开(公告)号：US09505748B2

公开(公告)日：2016-11-29

申请号：US14441183

申请日：2013-11-07

Applicant: Bristol-Myers Squibb Company

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Shuqun Lin ,  Steven H. Spergel ,  Yanlei Zhang

IPC: C07D417/12 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D237/24 ,  C07D413/12 ,  C07D413/14

CPC classification number: C07D417/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D237/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract translation: 具有下式I的化合物或其立体异构体或药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如本文所定义，可用于调节IL-12，IL-23和/或IFNα ，通过作用于Tyk-2引起信号转导抑制。

公开(公告)号：US20150299183A1

公开(公告)日：2015-10-22

申请号：US14441183

申请日：2013-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S, Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Zhang

IPC: C07D417/14 ,  C07D403/12 ,  C07D401/14 ,  C07D401/12

CPC classification number: C07D417/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D237/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Abstract translation: 具有下式I的化合物或其立体异构体或药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如本文所定义，可用于调节IL-12，IL-23和/或IFNα ，通过作用于Tyk-2引起信号转导抑制。

公开(公告)号：US20240124421A1

公开(公告)日：2024-04-18

申请号：US18539519

申请日：2023-12-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20220356180A1

公开(公告)日：2022-11-10

申请号：US17244938

申请日：2021-04-29

Applicant: Bristol-Myers Squibb Company

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Zhang ,  Qingjie Liu

IPC: C07D417/14 ,  C07D403/12 ,  C07D401/14 ,  C07D413/14 ,  C07D401/12 ,  C07D237/24 ,  C07D403/14 ,  C07D413/12 ,  C07D417/12 ,  C07B59/00

Abstract: Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20220119388A1

公开(公告)日：2022-04-21

申请号：US17503516

申请日：2021-10-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael C. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.